Skip to main content
ArticleOPEN ACCESS

Erratum: Evaluating Efficacy, Safety, and Pharmacokinetics after Switching from Infliximab Originator to Biosimilar CT-P13: Experience from a Large Tertiary Referral Center (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izz167)

Inflammatory Bowel Diseases
DOI: 10.1093/ibd/izz271
2Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Upon initial publication the supplementary data was omitted. This has been corrected and the supplementary data is included in the article. The publisher regrets this error.

Cite

CITATION STYLE

APA

Bronswijk, M., Moens, A., Lenfant, M., Tops, S., Compernolle, G., Van Assche, G., … Ferrante, M. (2020, January 1). Erratum: Evaluating Efficacy, Safety, and Pharmacokinetics after Switching from Infliximab Originator to Biosimilar CT-P13: Experience from a Large Tertiary Referral Center (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izz167). Inflammatory Bowel Diseases. Oxford University Press. https://doi.org/10.1093/ibd/izz271

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free